The Mayo SPORE in Brain Cancer comprises four investigator-initiated and led research projects, and four core resources constructed around a theme of malignant gliomas of adults. The Administrative Core provides a common management structure for the SPORE. This Core contributes to the overall efficiency of the SPORE and at the same time allows for economy of scale in its administrative and fiscal management. This in turn, frees investigators to concentrate on the science of the SPORE. The Administrative Core will support SPORE activities by providing: (1) Leadership, organizational support, and financial management for SPORE Investigators; (2) Coordination of monthly scientific meetings of SPORE investigators, and the ongoing scientific review of SPORE research projects and cores; (3) Information transfer to the scientific community via professional and public means; (4) Provision of common services for projects and cores such as administrative processing of reviews and funding statements, financial administration of grant funds, processing of IRB protocols and assurance of compliance with all NIH and Institutional grant regulations; (5) Coordination of the Internal and External Advisory Boards; (6) Oversight and management of the Developmental Research portfolio (Career Development Award; Developmental Research Award) of the SPORE; and, (7) Enhancement of communication between SPORE Investigators. The Administrative Core will foster Intra-SPORE, inter-SPORE, and intra-institutional collaborations; and, act as liaison with leadership of the other Brain SPOREs and the NCI SPORE Program.
Compared to other more common cancers malignant gliomas are responsible for a disproportionate amount of morbidity and mortality because of their disabling impact on cognition, memory, language, mobility, and adaptive skills. In addition to significant reduction in life expectancy each new case impacts the nation's public health since its morbidity represents on average twenty years of lost productivity. Whether the payer is public or private, diagnosis and treatment, including supportive care in the terminal stages of disease, extracts enormous health care expenditures.
|Geekiyanage, Hirosha; Galanis, Evanthia (2016) MiR-31 and miR-128 regulates poliovirus receptor-related 4 mediated measles virus infectivity in tumors. Mol Oncol 10:1387-1403|
|Rajani, Karishma; Parrish, Christopher; Kottke, Timothy et al. (2016) Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses. Mol Ther 24:166-74|
|Ma, Yufang; Tang, Nan; Thompson, Reid C et al. (2016) InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma. Clin Cancer Res 22:1767-76|
|Hardcastle, Jayson; Mills, Lisa; Malo, Courtney S et al. (2016) Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment. Neuro Oncol :|
|Vaubel, Rachael A; Chen, Selby G; Raleigh, David R et al. (2016) Meningiomas With Rhabdoid Features Lacking Other Histologic Features of Malignancy: A Study of 44 Cases and Review of the Literature. J Neuropathol Exp Neurol 75:44-52|
|Kurokawa, C; Geekiyanage, H; Allen, C et al. (2016) Alisertib demonstrates significant antitumor activity in bevacizumab resistant, patient derived orthotopic models of glioblastoma. J Neurooncol :|
|Zhang, Haoxing; Liu, Hailong; Chen, Yali et al. (2016) A cell cycle-dependent BRCA1-UHRF1 cascade regulates DNA double-strand break repair pathway choice. Nat Commun 7:10201|
|Lescarbeau, Rebecca S; Lei, Liang; Bakken, Katrina K et al. (2016) Quantitative Phosphoproteomics Reveals Wee1 Kinase as a Therapeutic Target in a Model of Proneural Glioblastoma. Mol Cancer Ther 15:1332-43|
|Kitange, Gaspar J; Mladek, Ann C; Schroeder, Mark A et al. (2016) Retinoblastoma Binding Protein 4 Modulates Temozolomide Sensitivity in Glioblastoma by Regulating DNA Repair Proteins. Cell Rep 14:2587-98|
|Cockle, Julia V; Rajani, Karishma; Zaidi, Shane et al. (2016) Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling. Neuro Oncol 18:518-27|
Showing the most recent 10 out of 220 publications